Efficacy of rituximab in immune thrombocytopenic purpura: A retrospective survey

Annals of Hematology

Volumn 91, Issue 2, 2012, Pages 279-285

  Brah, Souleymane ^a   Chiche, Laurent ^a   Fanciullino, Raphaelle ^a   Bornet, Charléric ^a   Mancini, Julien ^b   Schleinitz, Nicolas ^a   Jean, Rodolphe ^a   Kaplanski, Gilles ^a   Harlé, Jean Robert ^a   Durand, Jean Marc ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

B cell depletion; Immune thrombocytopenia; ITP; Rituximab

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DANAZOL; DAPSONE; ELTROMBOPAG; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RITUXIMAB; ROMIPLOSTIM; VINCRISTINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITAL INFECTION; HUMAN; HYPOTENSION; MALE; PRIMARY IMMUNE THROMBOCYTOPENIC PURPURA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY IMMUNE THROMBOCYTOPENIC PURPURA; SEPTIC SHOCK; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857368956     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1283-3     Document Type: Article

References (30)

1. DB Cines VS Blanchette 2002 Immune thrombocytopenic purpura N Engl J Med 346 995 1008 11919310 10.1056/NEJMra010501 (Pubitemid 34983251)
2. C Neunert W Lim M Crowther A Cohen L Solberg Jr MA Crowther 2011 The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia Blood 117 4190 4207 10.1182/blood-2010-08-302984 21325604 10.1182/blood-2010-08-302984 1:CAS:528:DC%2BC3MXls1GitbY%3D
3. M Khellaf JG Le Moine P Poitrinal C Francesconi A Haddad P Bierling M Michel L Eckert R Launois B Godeau 2011 Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis Ann Hematol 90 441 446 20922528 10.1007/s00277-010-1087-x
4. B Psaila JB Bussel 2008 Refractory immune thrombocytopenic purpura: current strategies for investigation and management Br J Haematol 143 16 26 18573111 10.1111/j.1365-2141.2008.07275.x 1:CAS:528:DC%2BD1cXht1ClsL7K
5. Haute Autorité de Santé (2009) ALD no. 2-Purpura thrombopénique immunologique de l'enfant et de l'adulte. Available at http://www.has-sante.fr/portail/jcms/c-896095/ald-n-2-purpura-thrombopenique- immunologique-de-l-enfant-et-de-l-adulte. Accessed October 2009
6. JC Edwards L Szczepanski J Szechinski A Filipowicz-Sosnowska P Emery DR Close RM Stevens T Shaw 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2572 2581 15201414 10.1056/NEJMoa032534 1:CAS:528:DC%2BD2cXkvFKntrc%3D (Pubitemid 38758544)
7. JH Stone PA Merkel R Spiera P Seo CA Langford GS Hoffman CG Kallenberg EW St Clair A Turkiewicz NK Tchao L Webber L Ding LP Ding K Mieras D Weitzenkamp D Ikle V Seyfert-Margolis M Mueller P Brunetta NB Allen FC Fervenza D Geetha KA Keogh EY Kissin PA Monach T Peikert C Stegeman SR Ytterberg U Specks RAVE-ITN Research Group 2010 Rituximab versus cyclophosphamide for ANCA-associated vasculitis N Engl J Med 363 221 232 20647199 10.1056/NEJMoa0909905 1:CAS:528:DC%2BC3cXptVKru78%3D
8. B Godeau R Porcher O Fain F Lefrère P Fenaux S Cheze A Vekhoff MP Chauveheid J Stirnemann L Galicier E Bourgeois S Haiat B Varet M Leporrier T Papo M Khellaf M Michel P Bierling 2008 Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study Blood 112 999 1004 18463354 10.1182/blood-2008-01-131029 1:CAS:528:DC%2BD1cXpvVOksLw%3D
9. F Zaja ML Battista MT Pirrotta S Palmieri M Montagna N Vianelli L Marin M Cavallin M Bocchia M Defina M Ippoliti F Ferrara F Patriarca MA Avanzini M Regazzi M Baccarani M Isola F Soldano R Fanin 2008 Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura Haematologica 93 930 933 18403395 10.3324/haematol.12206 1:CAS:528:DC%2BD1cXhsVWlur7O (Pubitemid 351821733)
10. G Bussone E Ribeiro A Dechartres JF Viallard B Bonnotte O Fain B Godeau M Michel 2009 Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases Am J Hematol 84 153 157 19123460 10.1002/ajh.21341 1:CAS:528:DC%2BD1MXktVelu7Y%3D
11. HA Liebman 2009 Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders Semin Hematol 46 S33 S36 19245932 10.1053/j.seminhematol.2008.12.004
12. B Terrier Z Amoura P Ravaud E Hachulla R Jouenne B Combe C Bonnet P Cacoub A Cantagrel M de Bandt O Fain B Fautrel P Gaudin B Godeau JR Harlé A Hot JE Kahn O Lambotte C Larroche J Léone O Meyer B Pallot-Prades E Pertuiset P Quartier T Schaerverbeke J Sibilia A Somogyi M Soubrier E Vignon B Bader-Meunier X Mariette JE Gottenberg Club Rhumatismes et Inflammation 2010 Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry Arthritis Rheum 62 2458 2466 20506527 10.1002/art.27541 1:CAS:528:DC%2BC3cXhtFOhsr7N
13. F Rodeghiero R Stasi T Gernsheimer M Michel D Provan DM Arnold JB Bussel DB Cines BH Chong N Cooper B Godeau K Lechner MG Mazzucconi R McMillan MA Sanz P Imbach V Blanchette T Kühne M Ruggeri JN George 2009 Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group Blood 113 2386 2393 19005182 10.1182/blood-2008-07-162503 1:CAS:528:DC%2BD1MXjsFKhurs%3D
14. B Godeau JM Durand F Roudot-Thoraval A Tennezé E Oksenhendler G Kaplanski A Schaeffer P Bierling 1997 Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases Br J Haematol 97 336 339 9163598 10.1046/j.1365-2141.1997.412687.x 1:CAS:528:DyaK2sXjsl2mtr0%3D (Pubitemid 27224614)
15. A Aleem AS Alaskar F Algahtani M Rather MH Almahayni A Al-Momen 2010 Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients Int J Hematol 92 283 288 20640541 10.1007/s12185-010-0635-4 1:CAS:528: DC%2BC3cXhtFalsrnL
16. R Stasi A Pagano E Stipa S Amadori 2001 Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 952 957 11493438 10.1182/blood.V98.4.952 1:CAS:528:DC%2BD3MXmtFeis70%3D
17. J Garcia-Chavez A Majluf-Cruz L Montiel-Cervantes MG Esparza J Vela-Ojeda Mexican Hematology Study Group 2007 Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis Ann Hematol 86 871 877 17874322 10.1007/s00277-007-0317-3 1:CAS:528: DC%2BD2sXht1ahu7fL
18. N Cooper R Stasi S Cunningham-Rundles MA Feuerstein JP Leonard S Amadori JB Bussel 2004 The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura Br J Haematol 125 232 239 15059147 10.1111/j.1365-2141.2004.04889.x 1:CAS:528:DC%2BD2cXktlKrsLk%3D (Pubitemid 38534976)
19. F Zaja N Vianelli M Battista A Sperotto F Patriarca V Tomadini C Filì M Tani M Baccarani R Fanin 2006 Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia Exp Hematol 34 571 572 16647558 10.1016/j.exphem.2006.02.009 1:CAS:528:DC%2BD28XjvVGhtbc%3D
20. DM Arnold F Dentali MA Crowther RM Meyer RJ Cook C Sigouin GA Fraser W Lim JG Kelton 2007 Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura Ann Intern Med 146 25 33 17200219 (Pubitemid 351650318)
21. FJ Peñalver V Jiménez-Yuste M Almagro A Alvarez- Larrán L Rodríguez M Casado L Gallur P Giraldo R Hernández D Menor MJ Rodríguez D Caballero R González J Mayans I Millán JR Cabrera Multi-institutional Retrospective Spanish Study Group on the Use of Rituximab in Refractory ITP 2006 Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients Ann Hematol 85 400 406 16550390 10.1007/s00277-006-0123-3 (Pubitemid 44283105)
22. C Schweizer FJ Reu AD Ho M Hensel 2007 Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab Ann Hematol 86 711 717 17622529 10.1007/s00277-007-0335-1 1:CAS:528:DC%2BD2sXpsVejsL0%3D (Pubitemid 47337933)
23. A Hasan M Michel V Patel R Stasi S Cunningham-Rundles JP Leonard J Bussel 2009 Repeated courses of rituximab in chronic ITP: three different regimens Am J Hematol 84 661 665 19731307 10.1002/ajh.21512 1:CAS:528:DC%2BD1MXhtlyqsLnL
24. D Dierickx G Verhoef A Van Hoof P Mineur A Roest A Triffet A Kentos P Pierre D Boulet G Bries PQ Lê A Janssens A Delannoy 2009 Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study J Intern Med 266 484 491 19549092 10.1111/j.1365-2796.2009.02126.x 1:CAS:528:DC%2BD1MXhsVyisbjL
25. AL Perrotta 2006 Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review Clin Appl Thromb Hemost 12 97 100 16444442 10.1177/107602960601200116 1:CAS:528:DC%2BD28Xhs1ans7k%3D (Pubitemid 43221579)
26. JE Gottenberg P Ravaud T Bardin P Cacoub A Cantagrel B Combe M Dougados RM Flipo B Godeau L Guillevin X Le Loët E Hachulla T Schaeverbeke J Sibilia G Baron X Mariette AutoImmunity and Rituximab Registry and French Society of Rheumatology 2010 Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry Arthritis Rheum 62 2625 2632 20506353 10.1002/art.27555 1:CAS:528: DC%2BC3cXht1ClurbP
27. S Pasa A Altintas T Cil R Danis O Ayyildiz 2009 The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura J Thromb Thrombolysis 27 329 333 18311541 10.1007/s11239-008-0208-z 1:CAS:528:DC%2BD1MXktV2iu74%3D
28. The ITP-RITUX Cohort: rituximab in immune thrombocytopenia Clinicaltrials.gov identifier NCT01101295. Available at http://clinicaltrials. gov/ct2/show/NCT01101295. Accessed April 2010
29. L Sailler 2008 Rituximab off label use for difficult-to-treat auto-immune diseases: reappraisal of benefits and risks Clin Rev Allergy Immunol 34 103 110 18270863 10.1007/s12016-007-8020-7 1:CAS:528:DC%2BD1cXkt1Kmurg%3D
30. DJ Kuter M Rummel R Boccia BG Macik I Pabinger D Selleslag F Rodeghiero BH Chong X Wang DP Berger 2010 Romiplostim or standard of care in patients with immune thrombocytopenia N Engl J Med 363 1889 1899 21067381 10.1056/ NEJMoa1002625 1:CAS:528:DC%2BC3cXhsVChtrbK